https://investors.modernatx.com/news-releases/news-release-details/moderna-covid-19-vaccine-retains-neutralizing-activity-against CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 25, 2021-- Moderna Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced results from in vitro neutralization studies of sera from individuals vaccinated with Moderna COVID-19 Vaccine showing activity against emerging strains of SARS-CoV-2. Vaccination with the Moderna COVID-19 Vaccine produced neutralizing titers against all key emerging variants tested, including B.1.1.7 and B.1.351, first identified in the UK and Republic of South Africa, respectively. The study showed no significant impact on neutralizing titers against the B.1.1.7 variant relative to prior variants. A six-fold reduction in neutralizing titers was observed with the B.1.351 variant relative to prior variants. Despite this reduction, neutralizing titer levels with B.1.351 remain above levels that are expected to be protective. This study was conducted in collaboration with the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases(NIAID), part of the National Institutes of Health (NIH). The manuscript has been submitted as a preprint to bioRxiv and will be submitted for peer-reviewed publication. The two-dose regimen of the Moderna COVID-19 Vaccine at the 100 µg dose is expected to be protective against emerging strains detected to date. Nonetheless, Moderna today announced its clinical strategy to proactively address the pandemic as the virus continues to evolve. First, the Company will test an additional booster dose of its COVID-19 Vaccine (mRNA-1273) to study the ability to further increase neutralizing titers against emerging strains beyond the existing primary vaccination series. Second, the Company is advancing an emerging variant booster candidate (mRNA-1273.351) against the B.1.351 variant first identified in the Republic of South Africa. The Company is advancing mRNA-1273.351 into preclinical studies and a Phase 1 study in the U.S. to evaluate the immunological benefit of boosting with strain-specific spike proteins. Moderna expects that its mRNA-based booster vaccine (whether mRNA-1273 or mRNA-1273.351) will be able to further boost neutralizing titers in combination with all of the leading vaccine candidates. For the B.1.1.7 variant, neutralizing antibody titers remained high and were generally consistent with neutralizing titers relative to prior variants. No significant impact on neutralization was observed from either the full set of mutations found in the B.1.1.7 variant or from specific key mutations of concern. Although these mutations have been reported to lessen neutralization from convalescent sera and to increase infectivity, sera from the Phase 1 participants and NHPs immunized with mRNA-1273 were able to neutralize the B.1.1.7 variant to the same level as prior variants. For the B.1.351 variant, vaccination with the Moderna COVID-19 Vaccine produces neutralizing antibody titers that remain above the neutralizing titers that were shown to protect NHPs against wildtype viral challenge. While the Company expects these levels of neutralizing antibodies to be protective, pseudovirus neutralizing antibody titers were approximately 6-fold lower relative to prior variants. These lower titers may suggest a potential risk of earlier waning of immunity to the new B.1.351 strains.
这是个好消息。而且今天拜登政府说要对南非impose travel ban。现在可能已经晚了,不过better than nothing. 我实在搞不懂这个南非的变种早就在讨论了,为啥这个travel ban 不早点实施。欧洲的travel ban 影响还大,这个南非断了也就断了,早断早好啊 surge 发表于 2021-01-25 10:22
这是个好消息。而且今天拜登政府说要对南非impose travel ban。现在可能已经晚了,不过better than nothing. 我实在搞不懂这个南非的变种早就在讨论了,为啥这个travel ban 不早点实施。欧洲的travel ban 影响还大,这个南非断了也就断了,早断早好啊 surge 发表于 2021-01-25 10:22
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 25, 2021-- Moderna Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced results from in vitro neutralization studies of sera from individuals vaccinated with Moderna COVID-19 Vaccine showing activity against emerging strains of SARS-CoV-2. Vaccination with the Moderna COVID-19 Vaccine produced neutralizing titers against all key emerging variants tested, including B.1.1.7 and B.1.351, first identified in the UK and Republic of South Africa, respectively. The study showed no significant impact on neutralizing titers against the B.1.1.7 variant relative to prior variants. A six-fold reduction in neutralizing titers was observed with the B.1.351 variant relative to prior variants. Despite this reduction, neutralizing titer levels with B.1.351 remain above levels that are expected to be protective. This study was conducted in collaboration with the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases(NIAID), part of the National Institutes of Health (NIH). The manuscript has been submitted as a preprint to bioRxiv and will be submitted for peer-reviewed publication.
The two-dose regimen of the Moderna COVID-19 Vaccine at the 100 µg dose is expected to be protective against emerging strains detected to date. Nonetheless, Moderna today announced its clinical strategy to proactively address the pandemic as the virus continues to evolve. First, the Company will test an additional booster dose of its COVID-19 Vaccine (mRNA-1273) to study the ability to further increase neutralizing titers against emerging strains beyond the existing primary vaccination series. Second, the Company is advancing an emerging variant booster candidate (mRNA-1273.351) against the B.1.351 variant first identified in the Republic of South Africa. The Company is advancing mRNA-1273.351 into preclinical studies and a Phase 1 study in the U.S. to evaluate the immunological benefit of boosting with strain-specific spike proteins. Moderna expects that its mRNA-based booster vaccine (whether mRNA-1273 or mRNA-1273.351) will be able to further boost neutralizing titers in combination with all of the leading vaccine candidates.
For the B.1.1.7 variant, neutralizing antibody titers remained high and were generally consistent with neutralizing titers relative to prior variants. No significant impact on neutralization was observed from either the full set of mutations found in the B.1.1.7 variant or from specific key mutations of concern. Although these mutations have been reported to lessen neutralization from convalescent sera and to increase infectivity, sera from the Phase 1 participants and NHPs immunized with mRNA-1273 were able to neutralize the B.1.1.7 variant to the same level as prior variants.
For the B.1.351 variant, vaccination with the Moderna COVID-19 Vaccine produces neutralizing antibody titers that remain above the neutralizing titers that were shown to protect NHPs against wildtype viral challenge. While the Company expects these levels of neutralizing antibodies to be protective, pseudovirus neutralizing antibody titers were approximately 6-fold lower relative to prior variants. These lower titers may suggest a potential risk of earlier waning of immunity to the new B.1.351 strains.
好消息
Moderna的疫苗起点很高,中和能力是康复血清的4倍,所以就算下降了还是有保护能力的,再加上T细胞免疫,短期内的保护效果应该还看得过去。但是体液免疫会随时间衰退,保护能力会慢慢下降,T细胞免疫能够避免重症但是很难完全预防有症状感染。现在Moderna已经开始做针对南非变种的booster shot了。
是不是也说明,另一方面也说明这病毒最后很可能就是应对流感的对付方法,疫苗每年,甚至每几个月改一下? 人类刚开始会抵抗,最后会逐步放弃抵抗跟新冠共存。
也不看看之前谁在台上,疯王下台前最后一天还莫名取消了所有covid相关travel restrictions, 拜登上台一周内能恢复而且加了个南非已经很不错了
前几年估计每年都要打针对新突变的booster shot。不过有一种可能是同时具有高传染性和高致病性的变种是有限的,病毒演化出了所有可能的突变之后一针多价疫苗可以提供好几年的保护。
我真觉得政策制定者应该每天来华人蹲点,这样可以更快发现很多苗头。感觉基本华人上的传闻,过一阵都成更真的了。
浣熊MM,我听过一个说法,就是这种病毒为了保证与ACE2的结合,所以变异逃逸的能力有限。以后会有疫苗能覆盖各种毒株。我不是你们专业的,请教一下是不是真的?
我担心会有original antigenic sin问题 打了booster,但是加强的是既认识野生型又认识突变型的克隆。。。。
另外,也期待J&J的疫苗上市
是的,等他们clinical trial的结果吧。。。说不定booster shot可以只用新突变的RBD部分做?
不要忘了一个基本的道理:病毒mutation是在繁殖过程中出现的。因此传染的人,繁殖量越少,新出现的mutation就会越少。 所以要大家都打疫苗,让这种突变每几年十几年才出现一次。
小浣熊MM,有没有关于T细胞免疫的比较全面的review你比较推荐的?比如提到了T细胞免疫如何避免重症之类的内容,谢谢哈